Impact of statins and ACE inhibitors on mortality after COPD exacerbations

Eric M. Mortensen, Laurel A. Copeland, Mary J V Pugh, Marcos I. Restrepo, Rosa M. de Molina, Brandy Nakashima, Antonio Anzueto

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations.Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.

Original languageEnglish (US)
Article number45
JournalRespiratory Research
Volume10
DOIs
StatePublished - Jun 3 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Chronic Obstructive Pulmonary Disease
Mortality
Angiotensin Receptor Antagonists
Preexisting Condition Coverage
Veterans
Hospital Mortality
Cohort Studies
Outpatients
Randomized Controlled Trials
Odds Ratio
Demography
Confidence Intervals

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Mortensen, E. M., Copeland, L. A., Pugh, M. J. V., Restrepo, M. I., de Molina, R. M., Nakashima, B., & Anzueto, A. (2009). Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respiratory Research, 10, [45]. https://doi.org/10.1186/1465-9921-10-45

Impact of statins and ACE inhibitors on mortality after COPD exacerbations. / Mortensen, Eric M.; Copeland, Laurel A.; Pugh, Mary J V; Restrepo, Marcos I.; de Molina, Rosa M.; Nakashima, Brandy; Anzueto, Antonio.

In: Respiratory Research, Vol. 10, 45, 03.06.2009.

Research output: Contribution to journalArticle

Mortensen, EM, Copeland, LA, Pugh, MJV, Restrepo, MI, de Molina, RM, Nakashima, B & Anzueto, A 2009, 'Impact of statins and ACE inhibitors on mortality after COPD exacerbations', Respiratory Research, vol. 10, 45. https://doi.org/10.1186/1465-9921-10-45
Mortensen, Eric M. ; Copeland, Laurel A. ; Pugh, Mary J V ; Restrepo, Marcos I. ; de Molina, Rosa M. ; Nakashima, Brandy ; Anzueto, Antonio. / Impact of statins and ACE inhibitors on mortality after COPD exacerbations. In: Respiratory Research. 2009 ; Vol. 10.
@article{c5b211764129405082b644e3d9c3e59d,
title = "Impact of statins and ACE inhibitors on mortality after COPD exacerbations",
abstract = "Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations.Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.Results: We identified 11,212 subjects with a mean age of 74.0 years, 98{\%} were male, and 12.4{\%} of subjects died within 90-days of hospital presentation. In this cohort, 20.3{\%} of subjects were using statins, 32.0{\%} were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95{\%} confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.",
author = "Mortensen, {Eric M.} and Copeland, {Laurel A.} and Pugh, {Mary J V} and Restrepo, {Marcos I.} and {de Molina}, {Rosa M.} and Brandy Nakashima and Antonio Anzueto",
year = "2009",
month = "6",
day = "3",
doi = "10.1186/1465-9921-10-45",
language = "English (US)",
volume = "10",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Impact of statins and ACE inhibitors on mortality after COPD exacerbations

AU - Mortensen, Eric M.

AU - Copeland, Laurel A.

AU - Pugh, Mary J V

AU - Restrepo, Marcos I.

AU - de Molina, Rosa M.

AU - Nakashima, Brandy

AU - Anzueto, Antonio

PY - 2009/6/3

Y1 - 2009/6/3

N2 - Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations.Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.

AB - Background: The purpose of our study was to examine the association of prior outpatient use of statins and angiotensin converting enzyme (ACE) inhibitors on mortality for subjects ≥ 65 years of age hospitalized with acute COPD exacerbations.Methods: We conducted a retrospective national cohort study using Veterans Affairs administrative data including subjects ≥65 years of age hospitalized with a COPD exacerbation. Our primary analysis was a multilevel model with the dependent variable of 90-day mortality and hospital as a random effect, controlling for preexisting comorbid conditions, demographics, and other medications prescribed.Results: We identified 11,212 subjects with a mean age of 74.0 years, 98% were male, and 12.4% of subjects died within 90-days of hospital presentation. In this cohort, 20.3% of subjects were using statins, 32.0% were using ACE inhibitors or angiotensin II receptor blockers (ARB). After adjusting for potential confounders, current statin use (odds ratio 0.51, 95% confidence interval 0.40-0.64) and ACE inhibitor/ARB use (0.55, 0.46-0.66) were significantly associated with decreased 90-day mortality.Conclusion: Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with a COPD exacerbation. Randomized controlled trials are needed to examine whether the use of these medications are protective for those patients with COPD exacerbations.

UR - http://www.scopus.com/inward/record.url?scp=70249144367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249144367&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-10-45

DO - 10.1186/1465-9921-10-45

M3 - Article

VL - 10

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 45

ER -